Speaker Bio & Presentations
Professor David Nutt
David Nutt is Chair of the Drug Science Scientific Committee and currently the Edmund J Safra Professor of Neuropsychopharmacology and Head of the Neuropsychopharmacology Unit in the Centre for Academic Psychiatry in the Division of Brain Sciences, Dept of Medicine, Hammersmith Hospital, Imperial College London. He is also visiting professor at the Open University in the UK and Maastricht University in the Netherlands. He is the founder of Drug Science and has held many leadership positions in both the UK and European academic scientific and clinical organizations. These include presidencies of the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology and the European College of Neuropsychopharmacology as well as Chair of the UK Advisory Council on the Misuse of Drugs. He is a Fellow of the Royal Colleges of Physicians, of Psychiatrists and of the Academy of Medical Sciences. He is also the UK Director of the European Certificate and Masters in Affective Disorders courses and a member of the International Centre for Science in Drug Policy.
David has edited the Journal of Psychopharmacology for over twenty five years and acts as the psychiatry drugs advisor to the British National Formulary. He has published over 500 original research papers and a similar number of reviews and books chapters, eight government reports on drugs and 35 books, including one for the general public, ‘Drugs Without the Hot Air’, which won the Transmission book prize in 2014 for Communication of Ideas.
Presentations & Workshops
Are So-Called Illegal Drugs the Future of Mental Health and Addiction Treatments?
The last two decades have seen a massive increase in innovation research relating to drugs that were (and in most cases still are) banned under the UN Conventions and national drugs legislation. Many of these drugs, particularly the psychedelics such as psilocybin and LSD had been shown to have significant benefits for mental health and addictions before they were banned in the 1960s/70s These early observations have since been confirmed with new studies of psilocybin in depression and addictions. More recently cannabis ketamine and MDMA have revealed efficacy in disorders such as PTSD depression and addiction. We are now in a new era of psychedelic-psychotherapy that offers a major advance for many patients who hitherto have not responded well to conventional treatments. Also, brain imaging research now helps us understand how these drugs work to facilitate the person engaging with the therapeutic process and why the impact of just one or two psychedelic interventions can lead to long-term benefits.
See More Speakers
The GXC Conference 2022 is dedicated to professionals who want to elevate their knowledge regarding therapeutic practices, treatment models, and the latest mental health, addiction, and wellness innovations.